Latest stories on KNSA
Impressive ARCALYST Growth and Strong Financials Signal Kiniksa's Momentum in 2026
July 28, 2026
MarketChameleon73 · bullishproduct/pr
Kiniksa projects $980M-$995M 2026 revenue guidance while advancing KPL-387 into Phase III PASTORALE
Seeking Alpha73 · bullishproduct/pr
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales Guidance
InvestorsHub71 · bullishearnings
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
Yahoo Finance68 · bullishearnings
Kiniksa Lifts ARCALYST Guidance Following 55% Growth and Positive Clinical Progress on KPL-387
July 28, 2026
MarketChameleon73 · bullishearnings
Kiniksa Pharmaceuticals International, plc GAAP EPS of $0.30 beats by $0.01, revenue of $243.6M beats by $17.14M
Seeking Alpha68 · bullishearnings
Kiniksa Pharmaceuticals International, plc (KNSA) files 8-K
SEC 8-K50 · neutralgeneral
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Business Insider56 · neutralearnings
Kiniksa Pharmaceuticals International, plc Q2 2026 Earnings Preview
Seeking Alpha56 · neutralearnings
Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 | KNSA Stock News
StockTitan50 · neutralgeneral
Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View
Yahoo Top67 · bullishproduct/pr
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences | KNSA Stock News
StockTitan56 · neutralproduct/pr
Kiniksa Pharmaceuticals Caps Major Shareholder Voting Control Rights
TipRanks50 · neutralgeneral
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
MarketBeat73 · bullishproduct/pr